NovoCure Management

Management criteria checks 3/4

NovoCure's CEO is Asaf Danziger, appointed in Jan 2002, has a tenure of 22.17 years. total yearly compensation is $2.28M, comprised of 36.4% salary and 63.6% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth $184.62K. The average tenure of the management team and the board of directors is 3.5 years and 6.3 years respectively.

Key information

Asaf Danziger

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage36.4%
CEO tenure22.2yrs
CEO ownership0.01%
Management average tenure3.5yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03
Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13
Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15
Is NovoCure (NASDAQ:NVCR) A Risky Investment?

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24
A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10
Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

NovoCure: See Past Market Myopia And Buy The Dip

Sep 27

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Sep 21

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Sep 09
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Sep 09

NovoCure Q2 2022 Earnings Preview

Jul 27

Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?

May 28
Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?

NovoCure: A Stalwart With More Upsides

May 09

NovoCure: Overview Of The GBM Business

Feb 28

Health Check: How Prudently Does NovoCure (NASDAQ:NVCR) Use Debt?

Feb 14
Health Check: How Prudently Does NovoCure (NASDAQ:NVCR) Use Debt?

NovoCure: Time For A Cure

Jan 01

NovoCure: Threshold Of Greatness

Nov 30

We Think NovoCure (NASDAQ:NVCR) Can Manage Its Debt With Ease

Oct 17
We Think NovoCure (NASDAQ:NVCR) Can Manage Its Debt With Ease

NovoCure: TTFields Generating Revenues And Creating Avenues For Further Growth

Sep 13

NovoCure (NASDAQ:NVCR) Might Have The Makings Of A Multi-Bagger

Sep 12
NovoCure (NASDAQ:NVCR) Might Have The Makings Of A Multi-Bagger

CEO Compensation Analysis

How has Asaf Danziger's remuneration changed compared to NovoCure's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$207m

Sep 30 2023n/an/a

-US$197m

Jun 30 2023n/an/a

-US$174m

Mar 31 2023n/an/a

-US$141m

Dec 31 2022US$2mUS$831k

-US$93m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$68m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$1mUS$876k

-US$58m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

US$12m

Dec 31 2020US$9mUS$782k

US$20m

Sep 30 2020n/an/a

US$19m

Jun 30 2020n/an/a

US$12m

Mar 31 2020n/an/a

US$9m

Dec 31 2019US$7mUS$702k

-US$7m

Sep 30 2019n/an/a

-US$27m

Jun 30 2019n/an/a

-US$41m

Mar 31 2019n/an/a

-US$55m

Dec 31 2018US$5mUS$693k

-US$64m

Sep 30 2018n/an/a

-US$59m

Jun 30 2018n/an/a

-US$59m

Mar 31 2018n/an/a

-US$64m

Dec 31 2017US$4mUS$698k

-US$62m

Compensation vs Market: Asaf's total compensation ($USD2.28M) is below average for companies of similar size in the US market ($USD5.09M).

Compensation vs Earnings: Asaf's compensation has increased whilst the company is unprofitable.


CEO

Asaf Danziger (57 yo)

22.2yrs

Tenure

US$2,278,951

Compensation

Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...


Leadership Team

NamePositionTenureCompensationOwnership
William Doyle
Executive Chairman20.2yrsUS$2.15m0.51%
$ 7.3m
Asaf Danziger
CEO & Director22.2yrsUS$2.28m0.013%
$ 184.6k
Ashley Cordova
Chief Financial Officer3.5yrsUS$6.84m0.066%
$ 938.4k
Wilhelmus C. Groenhuysen
Chief Operating Officer3.5yrsUS$6.62m0.17%
$ 2.4m
Frank Leonard
Executive VP & President of Novocure Oncology3.5yrsUS$6.13m0.045%
$ 640.7k
Yoram Palti
Founder & CTO24.2yrsUS$282.51kno data
Moshe Giladi
Chief Science Officer1.2yrsno data0.0065%
$ 92.5k
Ingrid Goldberg
VP of Investor Relationsno datano datano data
Barak Arye
General Counsel1.9yrsno data0.0099%
$ 139.4k
Michael Puri
Chief Human Resources Officerless than a yearno datano data
Uri Weinberg
Chief Innovation Officer1.2yrsno data0.058%
$ 816.7k
Piet Hinoul
Senior VPno datano datano data

3.5yrs

Average Tenure

54yo

Average Age

Experienced Management: NVCR's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
William Doyle
Executive Chairman20.2yrsUS$2.15m0.51%
$ 7.3m
Asaf Danziger
CEO & Director12.2yrsUS$2.28m0.013%
$ 184.6k
Jeryl Hilleman
Independent Director5.7yrsUS$445.20k0.0024%
$ 33.5k
David Hung
Independent Director5.8yrsUS$425.09k0.0063%
$ 88.6k
Timothy Scannell
Independent Director3.1yrsUS$439.44k0.000070%
$ 989.5
Kinyip Leung
Independent Director12.4yrsUS$432.70k0.070%
$ 993.8k
William Vernon
Lead Independent Director18.2yrsUS$481.54k0.15%
$ 2.1m
Martin Madden
Independent Director6.8yrsUS$446.26k0.015%
$ 206.2k
Kristin Stafford
Independent Directorless than a yearno datano data
Allyson Ocean
Independent Director1.1yrsno datano data

6.3yrs

Average Tenure

61yo

Average Age

Experienced Board: NVCR's board of directors are considered experienced (6.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.